1. Jacobson M McHutchison J Dusheiko G et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: final results of phase 3 ADVANCE study 2010
2. Kieffer T Bartels D Sullivan J et al. Clinical virology results from telaprevir phase 3 study ADVANCE 2010
3. Sherman K Flamm S Afdhal N et al. Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study 2010
4. Telaprevir phase 3 trial fact sheet http://wwwvrtxcom/current-projects/drug-candidates/telaprevir-VX-950html
5. Bronowicki J McCone J Bacon B et al. Response-guided therapy (RGT) with boceprevir (BOC) + peginterferon alfa-2b/ribavirin (P/R) for treatment-naïve patients with hepatitis C virus (HCV) genotype (G) 1 was similar to a 48-wk fixed-duration regimen with BOC + P/R in SPRINT-2 2010